Patient dies in Rocket gene therapy trial; Lilly’s $1B deal for a non-opioid pain biotech; A new dawn for psychedelics?; and more
Welcome back to Endpoints Weekly! The last week in May brought a lot of news, and it isn’t over yet. We’ve got reporters on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
